What is the equity of RemeGen Co this year?
RemeGen Co has equity of 3.44 B CNY this year.
RemeGen Co Equity 2024
RemeGen Co Equity
3.44 B CNY
Ticker
9995.HK
ISIN
CNE1000048G6
WKN
A2QGM4
In 2024, RemeGen Co's equity was 3.44 B CNY, a -30.98% increase from the 4.98 B CNY equity in the previous year.
RemeGen Co Aktienanalyse
What does RemeGen Co do?
RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing RemeGen Co's Equity
RemeGen Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding RemeGen Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating RemeGen Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
RemeGen Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in RemeGen Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about RemeGen Co stock
What was the equity of RemeGen Co compared to the previous year?
The equity of RemeGen Co has increased/decreased by -30.98% decreased compared to the previous year.
What impact does a high equity have on investors of RemeGen Co?
A high equity is advantageous for investors of RemeGen Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of RemeGen Co?
A low equity can be a risk for investors of RemeGen Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of RemeGen Co affect the company?
An increase in equity of RemeGen Co can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of RemeGen Co affect the company?
A reduction in equity of RemeGen Co can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of RemeGen Co?
Some factors that can affect the equity of RemeGen Co include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of RemeGen Co so important for investors?
The equity of RemeGen Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can RemeGen Co take to change the equity?
To change equity, RemeGen Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does RemeGen Co pay?
Over the past 12 months, RemeGen Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RemeGen Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of RemeGen Co?
The current dividend yield of RemeGen Co is .
When does RemeGen Co pay dividends?
RemeGen Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of RemeGen Co?
RemeGen Co paid dividends every year for the past 0 years.
What is the dividend of RemeGen Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is RemeGen Co located?
RemeGen Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von RemeGen Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of RemeGen Co from 12/17/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.
When did RemeGen Co pay the last dividend?
The last dividend was paid out on 12/17/2024.
What was the dividend of RemeGen Co in the year 2023?
In the year 2023, RemeGen Co distributed 0 CNY as dividends.
In which currency does RemeGen Co pay out the dividend?
The dividends of RemeGen Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von RemeGen Co
Our stock analysis for RemeGen Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
